Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Downloads
Exports from our negotiations database are available for download in CSV or JSON formats.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
In combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant durvalumab monotherapy, for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
Last updated:
April 29, 2026
Status:
Concluded with an LOI
Manufacturer:
Daiichi Sankyo Pharma Canada
Indication:
In combination with standard cytarabineand anthracycline induction and standard cytarabine consolidationchemotherapy, and as continuation maintenance monotherapy followingconsolidation, for the treatment of adult patients with newly diagnosed acutemyeloid leukemia (AML) that is FMS-like tyrosine kinase 3 internal tandemduplication (FLT3-ITD) positive.
Last updated:
April 29, 2026
Status:
Negotiations were not pursued
Manufacturer:
Apotex Inc.
Indication:
for the treatment of adults with recurrent unresectable or metastatic nasopharyngeal carcinoma (NPC) with disease progression on or after a platinum-containing chemotherapy
Last updated:
April 27, 2026
Enhertu (trastuzumab deruxtecan)
Status:
Active negotiation
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Advanced or Metastatic Gastric Cancer or Gastro-esophageal Junction (GEJ) Adenocarcinoma
Last updated:
April 21, 2026
Status:
Active negotiation
Manufacturer:
AbbVie Corporation
Indication:
Giant Cell Arteritis
Last updated:
April 13, 2026